BYSANTI (milsaperidone)

Clinical Therapeutics · Published 2026-05-14 · DOI 10.1016/j.clinthera.2026.05.003

Authors (1)

Paul Beninger

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Beninger, P. (2026). BYSANTI (milsaperidone). Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2026.05.003

Related articles

• Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder · ANNALS OF PHARMACOTHERAPY · 2026 · Cites or is cited by this article
• Mycotoxin Trends of Cannabis Compliance Testing in Cannabis Flower and Concentrates in the United States · Clinical Therapeutics · 2026 · Same journal
• Early-Onset Cannabis Use, Retinal Biomarkers, and Risk for Schizophrenia Preliminary Study · Clinical Therapeutics · 2026 · Same journal
• Novel Therapeutic Treatments in Perinatal Genetics Bridging Prenatal and Postnatal Care of Genetic Conditions · Clinical Therapeutics · 2026 · Same journal
• Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study · Clinical Therapeutics · 2026 · Same journal
• Implications of TLR4 Polymorphisms for Precision Therapeutics in Gram-negative Infections: An Ethnogeographic-Stratified Meta-Analysis · Clinical Therapeutics · 2026 · Same journal
• Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset · Clinical Therapeutics · 2026 · Same journal
• Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research · Clinical Therapeutics · 2026 · Same journal
• Benefits of Medical Cannabis in Patients With Pain Registered in the Minnesota Medical Cannabis Program · Clinical Therapeutics · 2026 · Same journal
• A Simultaneous Assessment of Efficacy and Safety of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease · Clinical Therapeutics · 2026 · Same journal